Loading...
XNAS
CHRS
Market cap93mUSD
Jul 03, Last price  
0.81USD
1D
1.87%
1Q
3.61%
Jan 2017
-97.12%
IPO
-94.64%
Name

Coherus BioSciences Inc

Chart & Performance

D1W1MN
P/E
3.29
P/S
0.35
EPS
0.25
Div Yield, %
—
Shrs. gr., 5y
9.43%
Rev. gr., 5y
-5.60%
Revenues
267m
+3.78%
1,899,0002,751,00031,106,00030,041,000190,106,0001,556,0001,556,000356,071,000475,824,000326,551,000211,042,000257,244,000266,960,000
Net income
29m
P
-33,018,000-53,635,000-87,133,000-223,260,000-127,337,000-238,170,000-209,339,00089,833,000132,244,000-306,322,000-326,628,000-237,892,00028,507,000
CFO
-20m
L-88.31%
-18,251,00015,423,000-23,927,000-107,990,000-252,545,000-200,286,000-159,266,00028,355,000154,145,000-37,432,000-241,124,000-174,884,000-20,440,000
Earnings
Aug 06, 2025

Profile

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
URL
https://www.coherus.com/
IPO date
Nov 06, 2014
Employees
294
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
266,960
3.78%
257,244
21.89%
211,042
-35.37%
Cost of revenue
210,889
272,219
467,922
Unusual Expense (Income)
NOPBT
56,071
(14,975)
(256,880)
NOPBT Margin
21.00%
Operating Taxes
(380)
34,874
Tax Rate
NOPAT
56,071
(14,595)
(291,754)
Net income
28,507
-111.98%
(237,892)
-27.17%
(326,628)
6.63%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,455
71,718
2,614
BB yield
-0.92%
-22.87%
-0.43%
Debt
Debt current
1,691
2,145
4,318
Long-term debt
234,801
484,025
480,422
Deferred revenue
Other long-term liabilities
64,925
11,459
92,746
Net debt
110,505
368,422
292,619
Cash flow
Cash from operating activities
(20,440)
(174,884)
(241,124)
CAPEX
(286)
(2,039)
Cash from investing activities
230,321
144,640
(166,850)
Cash from financing activities
(186,974)
69,600
54,326
FCF
92,522
152,661
(325,282)
Balance
Cash
125,987
117,748
191,681
Long term investments
440
Excess cash
112,639
104,886
181,569
Stockholders' equity
(1,551,256)
(1,579,737)
(1,341,849)
Invested Capital
1,717,397
1,878,613
1,772,553
ROIC
3.12%
ROCE
33.53%
EV
Common stock shares outstanding
114,830
94,163
77,630
Price
1.38
-58.56%
3.33
-57.95%
7.92
-50.38%
Market cap
158,466
-49.46%
313,562
-49.00%
614,830
-48.94%
EV
268,971
681,984
907,449
EBITDA
61,347
(11,184)
(253,181)
EV/EBITDA
4.38
Interest
27,158
40,542
32,474
Interest/NOPBT
48.44%